Newsgather

crispr

Stabil5 Meldungen4 QuellenZuletzt aktualisiert: 1.7.2026

Neueste Meldungen

Intellia's CRISPR Treatment Shows 87% Reduction in Hereditary Angioedema Attacks
In Entwicklung
Wissenschaft·27.4.2026KI-Zusammenfassung

Intellia's CRISPR Treatment Shows 87% Reduction in Hereditary Angioedema Attacks

Intellia Therapeutics' CRISPR-based treatment for hereditary angioedema met its goals in a Phase 3 trial, reducing attacks by 87% compared with placebo. The one-time infusion therapy edits genes directly in the liver and achieved 62% of patients being attack-free six months after treatment. The company has started a rolling FDA application and plans to launch in the first half of next year if approved.

C
CNBC
2 Min. Lesezeit